drugset / Trial / NCT06481306

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

NCT06481306

Phase 1/2 Recruiting 224 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.

Timeline

Start
2024-07-17
Primary completion
2028-04-30
Completion
2029-10-28

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986470 Unknown
Background Famotidine Other / unclassified
Background Pantoprazole Other / unclassified

Indications